Dr. Reddy's shares surged 1.7% on Nomura's bullish call and updates on its semaglutide and abbitacept drug pipeline

Mon 28 Sep 2026

Heard on Live TV News Channel between 15:04:59 - 15:06:14 IST.

• Dr. Reddy's stock rose 1.7% even as the broader market was weak, with Nomura turning bullish on the counter.
• Abbitacept, a drug for joint pain and inflammation, is on track for USFDA approval with a goal date of December 2026 and no queries received so far; launch planned immediately after approval.
• Biologics currently contribute 2% of revenue, seen as the next growth engine with more biosimilars in the pipeline.
• Semaglutide API impurity issue traced to scale-up batches; commercial supplies expected to resume from November with a target of 6-7 million pens between November and March.
• Management (M.V. Ramana) told Live TV News Channel that supply to Canada was paused for a few months but expected to resume in November, with more approvals expected in Latin America and beyond into FY28.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.